Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Shao Jian Lin"'
Autor:
Ze Rui Wu, Yong Zhang, Lin Cai, Shao Jian Lin, Zhi Peng Su, Yong Xu Wei, Han Bing Shang, Wen Lei Yang, Wei Guo Zhao, Zhe Bao Wu
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteri
Externí odkaz:
https://doaj.org/article/58d4856b04d74c5ebc9c9dc59aeb05bc
Autor:
Zhe Bao Wu, Chao Qiu, An Li Zhang, Lin Cai, Shao Jian Lin, Yu Yao, Qi Sheng Tang, Ming Xu, Wei Hua, Yi Wei Chu, Ying Mao, Jian Hong Zhu, Jianqing Xu, Liang Fu Zhou
Publikováno v:
Journal of Immunology Research, Vol 2014 (2014)
A2B5+ glioblastoma (GBM) cells have glioma stem-like cell (GSC) properties that are crucial to chemotherapy resistance and GBM relapse. T-cell-based antigens derived from A2B5+ GBM cells provide important information for immunotherapy. Here, we show
Externí odkaz:
https://doaj.org/article/499fd34acb6d49e7958777adb710144b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Houshi Xu, Shao Jian Lin, Tong Meng, Mingjie Wang, Anke Zhang, Meiqing Lou, Yunjia Ni, Yuanzhi Xu
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Glioma is one of the most typical intracranial tumors, comprising about 80% of all brain malignancies. Several key molecular signatures have emerged as prognostic biomarkers, which indicate room for improvement in the current approach to glioma class
Publikováno v:
Metabolic Brain Disease. 33:969-976
The aim of this study is to compare the efficacy of bromocriptine (BRC) versus cabergoline (CAB) in patients with giant prolactinomas. We searched MEDLINE, EMBASE, CENTRAL and Clinical Trials.gov for studies dated before March 1st, 2016, that used BR
Autor:
Miao-Yun, Long, Jin-Wu, Chen, Yue, Zhu, Ding-Yuan, Luo, Shao-Jian, Lin, Xin-Zhi, Peng, Lang-Ping, Tan, Hong-Hao, Li
Publikováno v:
Am J Transl Res
Purpose: The present study aimed to identify differentially expressed circRNAs in thyroid cancer and verify their potential functions. Methods: Next-generation sequencing was used to identify differentially expressed circRNAs between papillary thyroi
Publikováno v:
Neuroendocrinology. 110(6)
Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone production from these prolactinomas, but also causes tumour shrinka
Autor:
Yu Hang Guo, Zhi Gen Leng, Lin Cai, Ze Rui Wu, Zhe Bao Wu, Li Fei Wei, Shao Jian Lin, Jiang Long Lu, Zhi Peng Su, Kunlin Jin, Qi Chuan Zhuge
Publikováno v:
Endocrine. 52:641-651
Dopamine agonists (DAs) are the first-line treatment of prolactinomas. They function through the dopamine 2 receptor (D2R) in the tumor cells. Endocan, also called endothelial cell-specific molecule-1 (ESM1), has been described as a marker of neoangi
Autor:
Yu Hang Guo, Shao Jian Lin, Lin Cai, Weidong Le, Han Bing Shang, Wei Guo Zhao, Zhi Gen Leng, Yu Cai, Ning Li, Zhe Bao Wu
Publikováno v:
Oncotarget
Cabergoline (CAB), the first-line drug for treatment of prolactinomas, is effective in suppressing prolactin hypersecretion, reducing tumor size, and restoring gonadal function. However, mechanisms for CAB-mediated tumor shrinkage are largely unknown
Autor:
Shao Jian Lin, Yong Zhang, Weiguo Zhao, Yanting Liu, Zhe Bao Wu, Hong Yao, Hao Tang, Weiwei Rui
Publikováno v:
Neurosurgery. 85(4)
Background and importance Metastasis to the pituitary gland is uncommon in patients with systemic disseminated cancer. Individual articles have reported cases of pituitary metastasis mimicking a prolactinoma, but no case of a prolactin-secreting tumo